ME Therapeutics Holdings Inc.

OTCPK:METX.F Stock Report

Market Cap: US$60.4m

ME Therapeutics Holdings Management

Management criteria checks 0/4

ME Therapeutics Holdings' CEO is Salim Dhanji, appointed in Mar 2023, has a tenure of 1.58 years. directly owns 17.67% of the company’s shares, worth $10.68M. The average tenure of the management team and the board of directors is 1.6 years and 1.6 years respectively.

Key information

Salim Dhanji

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure1.6yrs
CEO ownership17.7%
Management average tenure1.6yrs
Board average tenure1.6yrs

Recent management updates

Recent updates


CEO

Salim Dhanji

1.6yrs

Tenure

Dr. Salim Dhanji is Chief Executive Officer and Director of ME Therapeutics Holdings Inc. from March 9, 2023. He serves as Head of Pre-Clinical Research at Qu Biologics Inc. Dr. Dhanji has done extensive p...


Leadership Team

NamePositionTenureCompensationOwnership
Salim Dhanji
CEO & Director1.6yrsno data17.67%
$ 10.7m
Quinn Martin
Chief Financial Officer1.6yrsUS$35.39kno data
Jamil Kassam
Corporate Secretary1.6yrsno datano data

1.6yrs

Average Tenure

Experienced Management: METX.F's management team is not considered experienced ( 1.6 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Salim Dhanji
CEO & Director1.6yrsno data17.67%
$ 10.7m
Kenneth Harder
Director1.6yrsno data17.64%
$ 10.7m
Karim Nanji
Director1.3yrsno datano data
John Priatel
Director1.6yrsno data17.67%
$ 10.7m

1.6yrs

Average Tenure

Experienced Board: METX.F's board of directors are not considered experienced ( 1.6 years average tenure), which suggests a new board.